| 53893-4 |
RNA polymerase III Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
RNA polymerase III Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
6 units (NOTE)Reference Range: <20 Units |
|
|
|
|
|
SERO |
|
53893-4 |
|
|
|
|
Both |
|
|
|
0 |
RNAp III Ab Ser-aCnc |
|
|
|
N |
|
3; ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Point in time; Pol III; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; RNAp III; Serology; Serum; SR |
2.73 |
2.26 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 53894-2 |
TRAPPC2 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
TRAPPC2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
FINAL REPORT (NOTE)TEST REQUESTED: SEDL METHODOLOGY: ALL CODING EXONS OF THE SEDL GENE WERE AMPLIFIED BY PCR. THE AMPLIFIED PRODUTS WERE THEN SEQUENCED USING ABI3730 SEQUENCERS AND ANALYZED FOR SEQUENCE VARIATIONS. THE SIGNIFICANCE OF THE VARIATIONS WAS DETERMINED BY COMPARISON WITH WILD TYPE SEQUENCES, PREVIOUSLY REPORTED MUTATIONS AND CORRELATION WITH SEDLIN PROTEIN STRUCTURE. ALTHOUGH DNA SEQUENCING IS A HIGHLY SENSITIVE METHODOLIGY, MUTATION DETECTION MAY NOT BE 100%. BACKGROUND: SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, X-LINKED (SEDT; MIM 313400) IS CAUSED BY MUTATIONS IN THE SEDL GENE. THUS, IT IS DISTINCT FROM COL2A1-RELATED SPONDYLOEPIPHYSEAL DYSPLASIA. ONSET IS TYPICALLY SEEN IN MALES BETWEEN THE AGES OF 10-14 YEARS. PATIENTS HAVE A SHORT TRUNK, VERTEBRAL FLATTENING WITH A CHARACTERISTIC ABNORMAL ACCUMULATION OF BONE, MILD EPIPHYSEAL DYSPLASIA OF THE LARGE JOINTS, PRECOCIOUS ARTHRITIS, AND OCHRONOSIS OF INTERVERTEBRAL DISCS. SEVERE OSTEOARTHRITIS MAY NECESSITATE TOTAL HIP ARTHROPLASTY BEFORE 40 YEARS OF AGE. OBLIGATE HETEROZYGOUS FEMALES MAY DISPLAY X-RAY CHANGES, BONE PAIN AND ARTHRITIS. RESULTS: DNA SEQUENCING OF THE SEDL GENE REVEALED NO DETECTABLE DISEASE CAUSING MUTATION. |
|
|
|
|
|
MOLPATH.MUT |
|
53894-2 |
|
Molgen |
|
|
Both |
|
|
|
0 |
TRAPPC2 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Document; Finding; Findings; Genetics; Heredity; Heritable; hYP38334; Inherited; MBP-1 interacting protein-2A; MBP-1-interacting protein 2A; MIP; MIP2A; MIP-2A; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; SEDL; SEDT; spondyloepiphyseal dysplasia, late; Tissue; Tissue, unspecified; trafficking protein particle complex 2; TRAPPC2P1; TRS20; WB; Whole blood; Whole blood or Tissue; ZNF547L |
2.68 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 53895-9 |
SH3BP2 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
SH3BP2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
FINAL REPORT (NOTE)TEST REQUESTED: SH3BP2 GENE/EXON 9/CHERUBISM RESULT: POSITIVE. HETEROZYGOUS P418H MUTATION IDENTIFIED IN THE SH3BP2 GENE. A HETEROZYGOUS C>A NUCLEOTIDE SUBSTITUTION WAS IDENTIFIED IN EXON 9, RESULTING IN THE REPLACEMENT OF A PROLINE CODON (CCC) WITH A HISTIDINE CODON (CAC) AT AMINO ACID POSITION 418. THIS MUTATION IS DENOTED p.Pro418His OR P418H. INTERPRETATION: THE P418H MISSENSE MUTATION IDENTIFIED IN THE SH3BP2 GENE OF THE SUBMITTED SPECIMEN HAS BEEN REPORTED PREVIOUSLY BY UEKI ET AL (NAT GENET, 28:125-126, 2001) AND IS CONSISTENT WITH THE CLINICAL DIAGNOSIS OF CHERUBISM IN THIS PATIENT. TO DATE, ALL REPORTED MUTATIONS IN SH3BP2 HAVE BEEN MISSENSE CHANGES LOCATED IN EXON 9 AND AFFECTING 4 RESIDUES WITHIN 6-AMINO ACID MOTIF (POSITIONS 415-420). RECOMMENDATION: TESTING OF OTHER AFFECTED FAMILY MEMBERS IS AVAILABLE AS IS PRENATAL DIAGNOSIS FOR THE PARENTS OF THIS CHILD. |
|
|
|
|
|
MOLPATH.MUT |
|
53895-9 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SH3BP2 gene Mut Anl Bld/T |
|
|
|
N |
|
3BP2; 3BP-2; Blood; Cherubism; CRBM; CRPM; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; RES4-23; SH3-domain binding protein 2; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 53896-7 |
SMC1A gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
SMC1A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
FINAL REPORT (NOTE)Test Requested: SEQUENCE ANALYSIS - SMC1A INDICATION: MENTAL RETARDATION - UNSPECIFIC RESULTS: NORMAL No mutation observed in the SMC1A gene. All 25 coding exons of the SMC1A gene were PCR amplified and sequenced in both forward and reverse directions from the patient's genomic DNA. No deleterious sequence changes were detected. The following polymorphism (benign sequence change) was detected: c.1-19C>T. INTERPRETATION DNA sequence analysis of the SMC1A gene did not demonstrate any abnormalities. Mutations in the SMC1A gene have been estimated to be present in approximately 5% of patients with Cornelia de Lange syndrome. The SMC1A gene does not appear to be implicated in this patient's disease phenotype. The etiology of the patient's disease phenotype therefore remains unknown. Genetic counseling is recommended. It should be noted that only the coding and immediate flanking regions of the SMC1A gene were analyzed by DNA sequencing. Changes in the promoter region and other non-coding regions will therefore not be detected by our assay. The DNA sequencing method of mutation detection employed has a sensitivity of 99-100% for the detection of nucleotide base alterations, small deletions and insertions. Our interpretation is based on the current understanding of the genetics of Cornelia de Lange syndrome. |
|
|
|
|
|
MOLPATH.MUT |
|
53896-7 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SMC1A gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; CDLS2; Document; DXS423E; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; SB1.8; SMC1; SMC1alpha; SMC1alpha protein; SMC1L1; SMCB; structural maintenance of chromosomes 1; structural maintenance of chromosomes 1A; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 53897-5 |
SPAST gene+KIAA0196 gene targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
SPAST gene + KIAA0196 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
MIN |
DefinitionDescription |
|
|
|
COMPLETE HEREDITARY SPASTIC PARAPLEGIA Interpretation NEGATIVE |
|
|
|
|
|
MOLPATH.MUT |
|
53897-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SPAST+KIAA0196 gene Mut Anl Bld/T |
|
|
|
N |
|
ADPSP; Blood; FSP2; Genetics; Heredity; Heritable; Identity or presence; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; Nominal; PCR; Point in time; Random; RTSC; SPAST+KIAA0196 gene; Spastic paraplegia 4; Spastic paraplegia 8; Spastin; SPG4; SPG4 gene; SPG8; strumpellin; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.63 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section. |
0 |
| 53898-3 |
KIAA0196 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
KIAA0196 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
53898-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
KIAA0196 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; RTSC; Spastic paraplegia 8; SPG8; strumpellin; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 53899-1 |
TGFBR1 gene+TGFBR2 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
TGFBR1 gene+TGFBR2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
(NOTE)TEST REQUESTED: TGFBRl + TGFBR2 METHODOLOGY: All 9 exons of the TGFBRl gene and the 7 exons of the TGFBR2 gene coding for transforming growth factor beta-receptor 1 and 2 were amplified by PCR. The amplified products were then sequenced using AB1 3730 sequencers and analyzed for sequence variations. The significance of the variations was determined by comparison with wild type sequences, previously reported mutations, and correlation with transforming growth factor beta-receptor 1 and 2 protein structures. Although DNA sequencing is a highly sensitive methodology, mutation detection may not be 100 %. BACKGROUND: Aortic aneurysm, familial thoracic 5 (AAT5; MIM 610380) and aortic aneurysm, familial thoracic 3 (AAT3; MIM 608976) have been linked to mutations in the transforming growth factor beta receptor type I and II genes (TGFBRl and TGFBR2), respectively. Patients may have aneurysms of the aorta and other arteries. TGFBR2 mutations are currently estimated to be responsible for about 5% of familial thoracic aortic aneurysm dissections. Inheritance is autosomal dominant. RESULTS: DNA sequencing of the TGFBRl and TGFBR2 genes did not reveal a disease causing mutation. |
|
|
|
|
|
MOLPATH.MUT |
|
53899-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
TGFBR1+TGFBR2 gene Mut Anl Bld/T |
|
|
|
N |
|
AAT3; AAT5; Activin receptor-like kinase 5; ACVRLK4; ALK5; ALK-5; Blood; Document; ESS1; FAA3; Finding; Findings; Genetics; Heredity; Heritable; HNPCC6; Inherited; LDS1; LDS1A; LDS1B; LDS2; LDS2A; LDS2B; MFS2; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MSSE; Mut; Mut Anl; Mutations; PCR; Point in time; Random; RIIC; Serine/threonine-protein kinase receptor R4; SKR4; TAAD2; tbetaR-I; TGF-beta receptor type-1 precursor; TGF-beta receptor type-2 precursor; TGFbeta-RII; TGFBR1+TGFBR2 gene; TGFR-1; TGFR-2; Tissue; Tissue, unspecified; transforming growth factor, beta receptor 1; transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kDa); transforming growth factor, beta receptor II (70/80kDa); WB; Whole blood; Whole blood or Tissue |
2.73 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 539-7 |
Mycobacterium sp |
Prid |
Sputum |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Mycobacterium sp identified in Sputum by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
539-7 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Mycobacterium Spt Cult |
|
|
|
|
|
Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Lower respiratory; Lung; Microbiology; Myco; Mycobact; Nominal; Point in time; Pulmonary; Pulmonology; Random; Respiratory; Spec; species; spp; Spt; Sputum; Tuberculosis |
2.78 |
1 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 5390-0 |
Toxoplasma gondii Ab.IgM |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Toxoplasma gondii IgM Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
Index |
|
|
|
|
|
|
MICRO |
|
5390-0 |
|
IA |
|
|
Both |
|
|
|
0 |
T gondii IgM Ser IA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; SUDS; T gondii; Toxo; Toxoplasmosis; UniversalLabOrders |
2.73 |
1 |
|
|
|
|
|
|
|
{Index_val} |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 53900-7 |
C10orf2 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
C10orf2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
(NOTE)TEST: DNA HELICASE TWINKLE GENE SEQUENCING RESULTS: DELETERIOUS MUTATIONS WERE NOT DETECTED INTERPRETATION: TEST RESULTS SHOULD BE INTERPRETED IN THE CONTEXT OF PATIENT'S CLINICAL PRESENTATION AND FAMILY HISTORY. DELETERIOUS MUTATIONS WERE NOT DETECTED. THIS ANALYSIS DID NOT DETECT LARGE HETEROZYGOUS DELETIONS OR DUPLICATIONS, OR MUTATIONS WITHIN THE PROMOTER OR DEEP INTRONIC REGIONS. |
|
|
|
|
|
MOLPATH.MUT |
|
53900-7 |
|
Molgen |
|
|
Both |
|
|
|
0 |
C10orf2 gene Mut Anl Bld/T |
|
|
|
N |
|
ATXN8; Blood; chromosome 10 open reading frame 2; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; IOSCA; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTDPS7; Mut; Mut Anl; Mutations; PCR; PEO; PEO1; PEOA3; Point in time; PRLTS5; Progressive external ophthalmoplegia; Random; SANDO; SCA8; Tissue; Tissue, unspecified; Twinkle; TWINL; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 53901-5 |
USH2A gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
USH2A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
53901-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
USH2A gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; dJ1111A8.1; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; RP39; Tissue; Tissue, unspecified; US2; USH2; Usher syndrome 2A; Usher syndrome 2A (autosomal recessive, mild); Usher syndrome type IIa protein; Usher syndrome type-2A protein; usherin; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 53902-3 |
Voriconazole |
MCnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Voriconazole [Mass/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
53902-3 |
|
|
|
|
Observation |
|
|
|
0 |
Voriconazole CSF-mCnc |
|
|
|
N |
|
Cerebral spinal fluid; Cerebrospinal Fl; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Vfend |
2.73 |
2.26 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 53903-1 |
Collection method |
Type |
Specimen |
Pt |
Nom |
|
|
ACTIVE |
Collection method - Specimen |
|
MIN |
DefinitionDescription |
|
|
|
capillary or venous |
|
|
|
|
|
SPEC |
|
53903-1 |
|
|
|
|
Observation |
|
|
|
0 |
Collection method Spec |
|
|
|
N |
|
Coll; Collect; Collected; Meth; Method of; Nominal; Point in time; Random; Spec; Typ |
2.73 |
2.26 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 53904-9 |
Observation |
Prid |
Sputum |
Pt |
Nom |
Rhodamine-auramine fluorochrome stain |
|
ACTIVE |
Microscopic observation [Identifier] in Sputum by Rhodamine-auramine fluorochrome stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53904-9 |
|
Rhodamine-auramine fluorochrome stain |
|
|
Both |
|
|
|
0 |
Rhodamine-auramine Stn Spt |
|
|
|
N |
|
AFB stain; Auramine stain; Auramine-Rhodamine stain; ID; Identity or presence; Infectious Disease; InfectiousDisease; Lower respiratory; Lung; Microbiology; Nominal; Point in time; Pulmonary; Pulmonology; Random; Respiratory; Rhodamine-auramine Stn; Spt; Sputum; St; Stains; Stn |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 53905-6 |
Observation |
Prid |
Urine |
Pt |
Nom |
Rhodamine-auramine fluorochrome stain |
|
ACTIVE |
Microscopic observation [Identifier] in Urine by Rhodamine-auramine fluorochrome stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53905-6 |
|
Rhodamine-auramine fluorochrome stain |
|
|
Both |
|
|
|
0 |
Rhodamine-auramine Stn Ur |
|
|
|
N |
|
AFB stain; Auramine stain; Auramine-Rhodamine stain; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random; Rhodamine-auramine Stn; St; Stains; Stn; UA; UR; Urn |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 53906-4 |
Observation |
Prid |
CSF |
Pt |
Nom |
Rhodamine-auramine fluorochrome stain |
|
ACTIVE |
Microscopic observation [Identifier] in Cerebral spinal fluid by Rhodamine-auramine fluorochrome stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53906-4 |
|
Rhodamine-auramine fluorochrome stain |
|
|
Both |
|
|
|
0 |
Rhodamine-auramine Stn CSF |
|
|
|
N |
|
AFB stain; Auramine stain; Auramine-Rhodamine stain; Cerebral spinal fluid; Cerebrospinal Fl; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Nominal; Point in time; Random; Rhodamine-auramine Stn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; St; Stains; Stn |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 53907-2 |
Observation |
Prid |
Plr fld |
Pt |
Nom |
Rhodamine-auramine fluorochrome stain |
|
ACTIVE |
Microscopic observation [Identifier] in Pleural fluid by Rhodamine-auramine fluorochrome stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53907-2 |
|
Rhodamine-auramine fluorochrome stain |
|
|
Both |
|
|
|
0 |
Rhodamine-auramine Stn Plr |
|
|
|
N |
|
AFB stain; Auramine stain; Auramine-Rhodamine stain; Identity or presence; Lung; Microbiology; Nominal; Pleural; Pleural fluid; Point in time; Pulmonary; Pulmonology; Random; Respiratory; Rhodamine-auramine Stn; St; Stains; Stn; thoracentesis fluid |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 53908-0 |
Bacteria |
Prid |
Esophageal brush |
Pt |
Nom |
Culture |
|
ACTIVE |
Bacteria identified in Esophageal brushing by Culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53908-0 |
|
Culture |
|
|
Both |
|
|
|
0 |
Bacteria Esoph Brush Cult |
|
|
|
N |
|
Bact; C&S; Cult; Cultures; Esoph Brush; Esophagial brush; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 53909-8 |
Mycobacterium sp |
Prid |
Plr fld |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Mycobacterium sp identified in Pleural fluid by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53909-8 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Mycobacterium Plr Cult |
|
|
|
N |
|
Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Lung; Microbiology; Myco; Mycobact; Nominal; Pleural; Pleural fluid; Point in time; Pulmonary; Pulmonology; Random; Respiratory; Spec; species; spp; thoracentesis fluid; Tuberculosis |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 5391-8 |
Toxoplasma gondii Ab.IgM |
Titr |
Ser/Plas |
Pt |
SemiQn |
IF |
|
ACTIVE |
Toxoplasma gondii IgM Ab [Titer] in Serum or Plasma by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
5391-8 |
|
IF |
|
|
Both |
|
|
|
0 |
T gondii IgM Titr SerPl IF |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SmQn; SR; T gondii; Time Resolved Fluorescence; Titer; Titered; Titre; Toxo; Toxoplasmosis; TRF; Ttr |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 53910-6 |
Observation |
Prid |
Periton fld |
Pt |
Nom |
Rhodamine-auramine fluorochrome stain |
|
ACTIVE |
Microscopic observation [Identifier] in Peritoneal fluid by Rhodamine-auramine fluorochrome stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53910-6 |
|
Rhodamine-auramine fluorochrome stain |
|
|
Both |
|
|
|
0 |
Rhodamine-auramine Stn Prt |
|
|
|
N |
|
AFB stain; Ascites; Ascitic fluid; Ascitis; Auramine stain; Auramine-Rhodamine stain; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Peritoneal fluid; Point in time; Prt; Random; Rhodamine-auramine Stn; St; Stains; Stn |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 53911-4 |
Bacteria |
Prid |
Bil fld |
Pt |
Nom |
Culture |
|
ACTIVE |
Bacteria identified in Bile fluid by Culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53911-4 |
|
Culture |
|
|
Both |
|
|
|
0 |
Bacteria Bifl Cult |
|
|
|
N |
|
Bact; BIFL; Bile fluid; Biliary fluid; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 53912-2 |
Observation |
Prid |
Body fld |
Pt |
Nom |
Rhodamine-auramine fluorochrome stain |
|
ACTIVE |
Microscopic observation [Identifier] in Body fluid by Rhodamine-auramine fluorochrome stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53912-2 |
|
Rhodamine-auramine fluorochrome stain |
|
|
Both |
|
|
|
0 |
Rhodamine-auramine Stn Fld |
|
|
|
N |
|
AFB stain; Auramine stain; Auramine-Rhodamine stain; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Fl; Fld; FLU; Fluid; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random; Rhodamine-auramine Stn; St; Stains; Stn |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 53913-0 |
Observation |
Prid |
Synv fld |
Pt |
Nom |
Rhodamine-auramine fluorochrome stain |
|
ACTIVE |
Microscopic observation [Identifier] in Synovial fluid by Rhodamine-auramine fluorochrome stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53913-0 |
|
Rhodamine-auramine fluorochrome stain |
|
|
Both |
|
|
|
0 |
Rhodamine-auramine Stn Snv |
|
|
|
N |
|
AFB stain; Auramine stain; Auramine-Rhodamine stain; ID; Identity or presence; Infectious Disease; InfectiousDisease; Joint aspirate; Joint fld; Joint flu; Joint fluid; Microbiology; Nominal; Point in time; Random; Rheum; Rheumatology; Rhodamine-auramine Stn; SF; SNV; St; Stains; Stn; Syn; Syn fl; Synov; Synovial fluid |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 53914-8 |
Observation |
Prid |
Endomet |
Pt |
Nom |
Rhodamine-auramine fluorochrome stain |
|
ACTIVE |
Microscopic observation [Identifier] in Endometrium by Rhodamine-auramine fluorochrome stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
53914-8 |
|
Rhodamine-auramine fluorochrome stain |
|
|
Both |
|
|
|
0 |
Rhodamine-auramine Stn Endometrium |
|
|
|
N |
|
AFB stain; Auramine stain; Auramine-Rhodamine stain; Endm; Endometr; Endometrium; Gyn; Gynecology; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; OB; ObGyn; Obstetrics; Point in time; Random; Rhodamine-auramine Stn; St; Stains; Stn |
2.78 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
